

Educating the next generation of PGx experts: global educational needs and concepts

Katja S Just¹, Richard M Turner², Vita Dolžan³, Erika Cecchin⁴, Jesse J Swen⁵, David Gurwitz⁶, Julia C Stingl^{1,7}

¹ Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany

² The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

³ Institute of Biochemistry, Faculty of Medicine, Ljubljana, Slovenia

⁴ Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy

⁵ Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands

⁶ Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

⁷ University Bonn, Medical Faculty, Centre for Translational Medicine, Bonn, Germany

Conflict of interest: All other authors declared no competing interests for this work.

Funding: This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 668353.

Keywords: pharmacogenomics, pharmacogenetics, education, dissemination, implementation

Correspondence:

Prof. Dr. med. Julia C. Stingl

Vice President

27 Head of Research Division
28 Federal Institute for Drugs and Medical Devices
29 Professor of translational pharmacology
30 University Bonn Medical School
31 Kurt-Georg-Kiesinger-Allee 3
32 53175 Bonn
33 Tel: +49 (0)228-99-307-3575
34 Fax: +49 (0)228-99-307-3217
35

36 **Introduction**

37 Despite being a well-established research discipline, pharmacogenomics (PGx) is not yet routinely
38 applied in patient care. Education is a crucial step for the successful implementation of PGx into the
39 clinic. We need to offer collaborative, interprofessional approaches that encourage learning about PGx
40 on an international level. It is especially important that PGx education enables the development of
41 one's own thoughts and ideas to be able to understand and implement this rapidly developing field of
42 science.

43

From science to patient care

PGx is a well-established field of science with more than 20,000 publications listed in the US National Library of Medicine National Institutes of Health (pubmed.gov) and more than 290,000 findings on google scholar to date for the terms 'pharmacogenetics' OR 'pharmacogenomics'. But implementing that knowledge into clinical practice and patient care seems highly heterogeneous and sporadic, except for a few large scientific efforts. Many barriers to implementing PGx in the clinic have been identified and are currently challenged (1), such as a lack of insurance coverage, harmonization of lab structures, procedures, data and interpretation of results. Regulatory authorities such as the Food and Drug Administration and the European Medicines Agency incorporate PGx information relating to drug efficacy and safety into product labels. International evidence based guidelines for treatment adjustments based on PGx results have been produced by CPIC and others and are available through the Pharmacogenomics Knowledge Base PharmGKB® and the CPIC website. Although PGx guidelines are published, in many countries medical specialty societies are not involved, recommend their use, or comment on their content. Increased knowledge about PGx is recognized as crucial for the implementation of PGx into clinical practice, and importantly the knowledge base within each country needs to be supported and built up to facilitate clinical implementation across multiple countries. A new generation of researchers and health-care professionals recognize the potential value that PGx offers to patient care. Despite PGx being a prominent field of research, its implementation into clinical practice remains hampered and haphazard. Because education in PGx is crucial for successful implementation, we need to offer collaborative approaches to disseminate PGx knowledge to the future generation of healthcare professionals and to develop the knowledge and skill sets to embrace PGx implementation.

A series of PGx educational programs and concepts for use in pharmacy and medical schools have been already proposed and undertaken (2). Unfortunately, education is often not providing definitive answers regarding how PGx testing can be obtained and applied to drug therapy.

Within the European Ubiquitous Pharmacogenomics (U-PGx) project, we performed a survey asking about general PGx knowledge in clinical practice (3). This survey was filled out by healthcare professionals and aimed to assess knowledge gaps and training needs that could be addressed by an educational program (4). The survey revealed that there is a general interest in PGx application. However, the interpretation of test results causes uncertainty, the medical knowledge is mainly limited to university centers, and could be improved especially in postgraduate education. Therefore, educating and training healthcare professionals of independent academic institutions such as universities seems to be one of the most important steps to close the gap between the research base and patient care.

The European perspective – Ubiquitous Pharmacogenomics (U-PGx) education program

Within the U-PGx implementation project, an educational program is offered that includes web-based seminars, e-learning opportunities, and real life courses (<http://upgx.eu/>).

We conducted a survey within the participants of a summer school that was part of the educational program of U-PGx. The group consisted of 49 participants from eight different countries (UK, Netherlands, Germany, Slovenia, Greece, Italy, Portugal, and Canada) and worked in hospitals (35%), ambulatories (7.5%), and academia (57.5%). Whilst researchers and students were commonly attending the course (51.2%), just 16.3% were physicians working in patient care, and 27.9% were pharmacists. Figure 1a) provides an overview of the availability of PGx tests in hospital settings, indications for ordering a PGx test, and locations of PGx data storage as reported by participants of the U-PGx course.

Figure 1

Survey responses of this sample indicated that, within Europe, the utility of PGx is mainly limited to the research domain, with the local laboratory that generated the PGx data responsible for storage of

the PGx results; these characteristics are consistent with commonly described barriers to PGx implementation to patient care (1). Despite the interest in PGx in young health care professionals that participated in the U-PGx course, there is still a lack of translation of PGx knowledge from the laboratory and research structures into the clinic.

We also investigated the perceived importance, attributed by the course participants, for several established drug-gene pairs that have CPIC guidelines available. Figure 1b) shows how the drug-gene pairs were rated by the participants according to their perceived importance.

When considering drug classes, antithrombotic, and antineoplastic and immunomodulating agents were ranked the most, presumably because these drugs are associated with severe adverse drug reactions such as bleeding or leucopenia. The large number of drug-gene pairs concerning drugs acting on the central nervous system can also be appreciated from figure 1b), as numerous drugs that act on the central nervous system are metabolized by highly polymorphic cytochrome P450 enzymes (especially *CYP2D6* and *CYP2C19*).

Although revealed by a small sample, these findings are in line with the perceived meaning of drug-gene pairs as rated by members of the American Society for Clinical Pharmacology and Therapeutics in 2010 (5). However, a survey addressing a larger and broader population including also more physicians would be desirable.

For the U-PGx summer school, a comprehensive curriculum was developed that focuses on PGx knowledge, skills and attitude towards PGx. Table 1 provides the curriculum and didactic goals of the course illustrating that health professionals need to acquire knowledge and skills to empower them to practice evidence-based precision medicine.

Table 1

What education should address

Education of healthcare professionals: knowledge, skills, attitudes

Education in PGx should focus on knowledge and skills development, such as how to interpret test results and how to put the results into context when making treatment decisions. In addition, health care professionals' attitudes which mean thoughts and views that may change the use of PGx in patient care need to be addressed. In a globalized world, we need to foster attitudes towards implementing PGx, such as considerations when a PGx test is reasonable or should be done independent of ethnic background or reimbursement features of single countries, and even if it is not covered by available treatment guidelines. These skills and attitudes might be the crucial step for implementation as most clinics do not offer a pre-emptive approach. Therefore, implementation also means anticipation of clinical situations when testing might be required. Furthermore, education needs to help bridge the gap between PGx treatment guidelines and clinical reality, for instance by training healthcare practitioners how to interpret and use a genotype-predicted phenotype in the context of interacting drugs and comorbidities that also affect drug disposition (e.g. hepatic disease, chronic kidney disease). The available PGx guidelines provide already excellent and reliable information on drug-gene interactions and the need for treatment modification. However, those guidelines are tools and, even though easily available, we need to offer education on how to use those tools.

...and beyond: Education of patients in health competence

It should not be neglected that the general population's awareness about PGx is increasing, which is expected to push conservative healthcare professions towards greater use of PGx. Therefore, information initiatives that target both patients and the wider public should be considered to stimulate healthcare professionals' interest in PGx as a beneficial byproduct. To that end, the U-PGx project provides valuable educational materials which are freely available (<http://upgx.eu/>).

An interdisciplinary approach between physicians and pharmacists on the one side and research personal and allied health care professionals on the other side is essential for tackling the most difficult questions regarding the application of PGx and to offer opportunities to learn from each other.

Interdisciplinary education has been shown to enhance learning in the health care setting and PGx should not be an exception.

Interdisciplinary work

In our own experience, it is highly beneficial, appreciated, and indeed encouraged to work through interdisciplinary collaborations that foster our own thinking, recognize the multiple aspects involved in making a treatment decision and thus do not always simply offer a single concrete answer. It is preferable in PGx education that lecturers engage and encourage team work among and between specialties. As pointed out technical and conceptual developments in PGx are ongoing. Therefore, besides imparting knowledge to empower the understanding of PGx testing and treatment concepts, we need education that equips individuals with the skills to develop their own thoughts and ideas. Thereby, health care professionals might be enabled to understand and apply this rapidly developing field of science in a safe and informed manner. Thus, interdisciplinary collaboration and personal contact with the patient remain central tenets of any comprehensive PGx implementation program. Science needs to connect closely to clinic and the healthcare setting should not be afraid of science to overcome the gap between the two of them. The specialty of clinical pharmacology might be particularly well suited to linking these fields to accelerate the successful translation of PGx from the bench to the bed.

Acknowledgements

We would like to thank all U-PGx summer school speakers who enriched the U-PGx summer school with enthusiastic and brilliant talks: Evangelina Tsermpini, Richard Turner, Vita Dolžan, Jesse Swen, Rachel Hubbard, Leigh Jackson, Jürgen Brockmüller, David Gurwitz, and Erika Cecchin. We also thank the supporting team at the Federal Institute for Drugs and Medical Devices in Bonn. Last but not least, we thank all participants of the U-PGx summer school, for an inspiring week, their interest, enthusiasm, and active participation.

172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196

Author Contributions: KJ designed the questionnaires and educational material within the U-PGx study and drafted the manuscript. JS supervised development of educational material and designed the outline for the manuscript. RT supported development of educational strategies for the U-PGx summer school. DG supervised the U-PGx workshop. RT, VD, EC, JS, and DG all participated as speakers at the U-PGx summer school. All authors collaborated in writing and approved the final manuscript.

References

(1) Shuldiner, A.R. *et al.* The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. *Clin Pharmacol Ther* 94, 207-10 (2013).

(2) Dunnenberger, H.M. *et al.* Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Annu Rev Pharmacol Toxicol* 55, 89-106 (2015).

(3) van der Wouden, C.H. *et al.* Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. *Clin Pharmacol Ther* 101, 341-58 (2017).

(4) Just, K.S., Steffens, M., Swen, J.J., Patrinos, G.P., Guchelaar, H.J. & Stingl, J.C. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). *Eur J Clin Pharmacol* 73, 1247-52 (2017).

(5) Relling, M. & Klein, T. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. *Clin Pharmacol Ther* 89, 464-7 (2011).


197 Table 1: Educational needs identified and addressed in a four day U-PGx course

Learning Goal	Learning Objective	Educational Strategy	Learning Domain
Drug distribution and tolerance affected by PGx	Participant learns about the potential influence of PGx on phase I and II enzymes	Teacher-based instruction	Knowledge
	Participant learns about the potential influence of PGx on HLA genes and transporters	Teacher-based instruction	Knowledge
Concepts of PGx guided therapy	Participant understands ways of how PGx knowledge can guide treatment decisions	Teacher-based instruction	Knowledge
Selection of patients to genotype	Participant can identify cases where a PGx test should be done	Case-based learning	Skills
	Participant can appraise critical benefits of PGx tests and risks of treating without a PGx test	Case-based learning	Attitudes
	Participant can identify cases when it is reasonable to request a PGx test	Case-based learning	Skills
Interdisciplinary collaboration	Participant can discuss PGx topics within an interdisciplinary team	Case-based learning	Skills
	Participant can appraise different levels of knowledge about PGx and develop strategies within a team	Case-based learning	Attitudes
Methods of genotyping	Participants learn about different genotyping techniques and their influence on test results	Teacher-based instruction	Knowledge
PGx databases and resources	Participant learns about available databases and other clinical relevant resources such as PharmGKB or PharmVar to inform himself on clinical relevant PGx knowledge	Teacher-based instruction with online presentation	Knowledge

Interpretation of test results	Participant learns to translate common genotypes into phenotypes	Case-based learning	Skills
	Participant considers the integration of genotype results with co-medications, and comorbidities	Case-based learning	Skills
Ethical and legal aspects of PGx	Participant understands ethical and legal aspects pertaining to PGx	Teacher-based instruction	Knowledge/ Attitudes
Ethical considerations	Participant learns strategies on how to inform patients about genotyping in different situations such as direct to consumer genotyping or genome project genotyping	Case-based learning	Attitudes
	Participant learns how to obtain informed consent for genotyping in different situations such as direct to consumer genotyping or genome project genotyping	Case-based learning	Attitudes
Clinical impact of structures affected by polymorphisms on drug treatment	Participant learns about and understands important and common sequence variations that impact drug therapy	Teacher-based instruction	Knowledge
PGx based treatment modifications	Participant can appraise dose modifications and contra-indications	Case-based learning	Skills/ Attitudes
	Participant learns to use PGx test results within patients' contexts when making treatment decisions	Case-based learning	Skills
History of PGx	Participant can integrate his PGx knowledge in scientific developments of the last years	Teacher-based instruction	Skills/ Knowledge
Implementation of PGx	Participant learns about examples and structures from clinical reality for	Teacher-based instruction	Knowledge

successful implementation of PGx into
patient care

198



200

201 **Figure:**

202 a) Answers to a survey concerning availability of PGx test (red), reason for ordering a PGx test (blue),

203 and PGx test data storage (turquoise).

204 Participants were able to choose more than one answer. Public: health insurances, public health

205 system; private: companies; In-house: hospital, laboratory; DTC: direct-to-consumer;

206 b) Importance of drug-gene pairs as rated by participants. Percentages of participants ranking the ten
207 most important drug-gene pairs from a list of 56 pairs of drug-gene pairs available CPIC guidelines are
208 shown.

209 The color of each bar indicates the class of the drug in the drug-gene pairs: red: antithrombotics;
210 orange: anti-infectives; brown: antineoplastic and immunomodulating agents; turquoise: drugs acting
211 on the central nervous system; green: drugs acting on the cardiovascular system; purple: drugs acting
212 on the musculo-skeletal system; yellow: drugs acting on the alimentary tract and metabolism; grey:
213 others: antiparasitic products and drugs acting on the respiratory system

214 CYP: cytochrome P450, VKORC1: vitamin K epoxide reductase complex subunit 1, HLA: human
215 leukocyte antigen, SLCO1B1: solute carrier organic anion transporter family member 1B1, TPMT:
216 Thiopurine methyltransferase, UGT1A1: uridine diphosphate glucuronosyltransferase, DPYD:
217 dihydropyrimidine dehydrogenase, OCT: organic cation transporter, CFTR: cystic fibrosis
218 transmembrane conductance regulator, IFNL3: interleukin 28B, NAT2: N-acetyltransferase 2.

219

220 Responder rate: n=40 (82%, total: 49 participants from 8 different countries (UK, Netherlands,
221 Germany, Slovenia, Greece, Italy, Portugal, and Canada)

222